Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
627 clinical trials found
Clinical trials

ACTM-838

A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of ACTM-838 as a Single Agent in Patients with Advanced Solid Tumors (NCT06336148)

Currently recruiting

ADAPT-TDM

A beta-lactam antibiotic Dose Adaptation Pilot randomised controlled Trial utilising Therapeutic Drug Monitoring (ADAPT-TDM) (ACTRN12623000032651)

Currently recruiting

ADOPT-LUNG ETOP 25-23

An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC (ACTRN12624001373561)

Currently recruiting

ADVANCE-extension

A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION (ADVANCE-extension) (NCT03683186)

Currently recruiting

ADVANCE-outcomes

A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients (ADVANCE-outcomes) (NCT03626688)

Currently recruiting

AER-01

A Phase 2a, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fexlamose [AER-01] Inhalation Solution in the Treatment of Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease (NCT06731959)

Currently recruiting

AF and sexual dysfunction

Assessing the impact of atrial fibrillation and catheter ablation on sexual function: an observational study (Trial Not Registered)

This study aims to ask patients about how their AF has affected intimate relationships and whether catheter ablation has any effect on this.
Currently recruiting

AFFINE

Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C<=1%) (NCT04370054)

No longer recruiting

AFMR_TTE

Outcomes of Surgery for Atrial Functional Mitral Regurgitation (ACTRN12624000705583)

No longer recruiting

AHSCT in MS

A Phase II observational study: autologous haematopoietic stem cell transplantation for highly active treatment resistant multiple sclerosis (ACTRN12616000151437)

Currently recruiting

AK-US-001-0105 - NASH

A Phase 3, Randomized, Double-blind, Placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with non-cirrhotic nonalcoholic steatohepatitis (NASH) and fibrosis. (NCT06215716)

Currently recruiting

AK-US-001-0106

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis [NASH]/Metabolic Dysfunction-Associated Steatohepatitis [MASH] (NCT06528314)

Currently recruiting

ALLAY-HFrEF

Safety and Efficacy of the Alleviant No-Implant Interatrial Shunt in Patients with Heart Failure and Reduced Ejection Fraction (NCT06812533)

This study is to evaluate the safety and efficacy of the Alleviant ALV1 System in patients with reduced ejection fraction (HFrEF), who remain symptomatic despite optimal maximally tolerated guideline directed medical therapy (GDMT).
Coming soon

Alpha Orbit - STAR0215-301

A Phase 3, Multicenter, randomised, double-blind, placebo controlled trial to evaluate the efficacy and safety of Navenibart in participants with Hereditary Angioedema (NCT06842823)

Navenibart is being developed as a prophylactic treatment for the prevention of Hereditary Angioedema attacks.
Coming soon

Alpha-9 GRPR Study

A Phase 1 Study Investigating the Safety, Tumor Uptake, Biodistribution, and Dosimetry of [68Ga]Ga-A9-6217 in Participants with Select Advanced or Metastatic Solid Tumors (ACTRN12625000268448)

A study is testing a new diagnostic product, to detect tumour tissue throughout the body using a radioactive substance a positron emission tomography (PET) tracer, that targets a protein Gastrin-Releasing Peptide Receptor (GRPR) which is found in various cancer types. This is not a treatment study. No treatment will be provided to you as part of this study. This study is testing a new imaging product only.
Coming soon

Alterity ATH

A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy (NCT05109091)

Currently recruiting

AMALTHEA AZD7798

A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients with Moderate to Severe Crohns Disease [AMALTHEA] (NCT06450197)

This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 subcutaneous (SC) every 4 weeks (Q4W) in participants with moderate to severe Crohns disease. The objectives of this study will be evaluated in a broad Crohns disease population, and in predefined subpopulations, according to the areas of active inflammation (ileal/ileocecal [L1], colonic [L2], ileocolonic [L3]).
Currently recruiting

AMaRC 21-04

Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The RIDDLE-M-X trial (ACTRN12622001366741)

Currently recruiting

AMEND-CRT

Assessment of MEchaNical Dyssynchrony versus standard selection on clinical response in candidates for Cardiac Resynchronization Therapy – The AMEND-CRT Trial (NCT04225520)

Currently recruiting

AMG509

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy (NCT06691984)

Currently recruiting
1 2 3 4